# FDA Approves First-in-Class Relacorilant for Platinum-Resistant Ovarian Cancer

> fda · REPORTED · 2026-03-01

In Q1 2026, the FDA approved relacorilant (Lifyorli) in combination with nab-paclitaxel as the first-in-class selective glucocorticoid receptor antagonist for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have received at least one prior systemic therapy. This represents a landmark first approval for a new mechanism in this difficult-to-treat gynecologic cancer setting.

About Relacorilant / Corcept Therapeutics: Corcept Therapeutics develops selective glucocorticoid receptor modulators for cancer and metabolic conditions, with relacorilant designed to block glucocorticoid signaling that enables tumors to evade chemotherapy.

- Company: Relacorilant / Corcept Therapeutics
- Sector: oncology
- Primary source: https://www.aacr.org/blog/2026/04/01/fda-approvals-in-oncology-january-march-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.